DaVita Inc. (DVA)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $bn | 12 | 12 | 12 | 12 | 13 | 14 | 14 | 14 |
| Operating profit | $bn | 2 | 2 | ||||||
| Net profit | $bn | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EPS reported | $ | 9.51 | 11.38 | ||||||
| Operating cashflow per share | $ | 21.91 | 33.85 | ||||||
| Capex per share | $ | 6.69 | 9.00 | ||||||
| FCF per share | $ | 15.22 | 24.85 | ||||||
| Free cash flow | $bn | 1 | 2 | ||||||
| Net debt | $bn | 12 | 8 | ||||||
| Book value equity | $bn | -1 | -1 | ||||||
| Book value per share | $ | -7.39 | -11.58 | ||||||
| Number of shares | m | 88.1 | 66.09 | ||||||
| DPS (TTM paid) | $ | 0.00 | 2.27 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 11.95 | 15.68 | ||||||
| P/B LTM | x | -15.02 | -12.79 | ||||||
| P/S LTM | x | 0.72 | 0.70 | ||||||
| P/FCF LTM | x | 7.46 | 6.08 | ||||||
| EV/EBITDA LTM | x | 9.11 | 8.71 | ||||||
| EV/Sales LTM | x | 1.76 | 1.55 | ||||||
| Earnings Yield LTM | % | +8.37% | +6.38% | ||||||
| FCF Yield | % | +13.40% | +16.46% | ||||||
| Quality | |||||||||
| ROE | % | -114.70% | -123.56% | ||||||
| ROIC | % | +10.58% | +11.18% | ||||||
| Operating margin | % | +14.74% | +15.06% | ||||||
| Gross margin | % | +27.00% | +31.02% | ||||||
| FCF/Sales | % | +9.61% | +11.49% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | -11.37% | +6.06% | ||||||
| Sales Growth YoY | % | +6.46% | +9.32% | ||||||
| Net Income Growth YoY | % | -20.24% | -9.49% | ||||||
| FCF Growth | % | -10.63% | +9.75% | ||||||
| Operating Profit Growth | % | -3.82% | +0.92% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | +17.75% | ||||||
| FCF/Debt | x | 0.09 | 0.15 | ||||||
| Net Debt/EBITDA | x | 5.41 | 3.66 | ||||||
| EBIT/Net interest | x | 3.66 | 3.77 | ||||||
| Net debt/market cap | % | +1.27% | +93.26% | ||||||
| Net debt/Equity | x | -17.92 | -10.33 | ||||||
| Gross debt/equity | x | -23.12 | -14.09 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free